Can I Take Resveratrol with a Hormonal IUD (Mirena or Kyleena)?

What resveratrol actually does in the body

Resveratrol is a polyphenol found in grape skin, red wine, and Japanese knotweed, sold widely as a longevity and anti-inflammatory supplement. At the doses women typically take (250 mg to 1,000 mg per day), it acts through several overlapping pathways that are relevant if you are using a hormonal IUD.

How resveratrol is metabolized: the CYP3A4 question

Resveratrol is metabolized primarily by sulfation and glucuronidation, but it also inhibits CYP3A4 and CYP1B1 in vitro. CYP3A4 is the enzyme that breaks down many oral hormonal contraceptives, so the theoretical concern is real: if resveratrol slows CYP3A4, it could raise the plasma concentration of a co-administered oral progestin or estrogen.

The practical significance for an IUD user is much smaller. Mirena (levonorgestrel 52 mg) and Kyleena (levonorgestrel 19.5 mg) deliver hormone directly into the uterine cavity. Systemic absorption is intentionally minimal. Mirena produces a mean plasma levonorgestrel concentration of roughly 150 to 200 pg/mL, compared with 1,500 to 2,000 pg/mL from a levonorgestrel-only oral pill. At those low plasma concentrations, even a moderate CYP3A4 inhibitor would produce a clinically insignificant rise in circulating levonorgestrel. Your contraceptive protection comes from local endometrial and cervical effects, not from a threshold blood level.

Resveratrol's weak estrogenic activity

Resveratrol binds estrogen receptor alpha and estrogen receptor beta, acting as a selective estrogen receptor modulator. In receptor-binding studies it shows affinity roughly 1/1,000 to 1/7,000 that of estradiol, which is weak but not zero. The LNG-IUD works partly by thinning the endometrial lining. A compound with mild estrogenic activity could, in theory, partially oppose that local effect, though no clinical study has demonstrated this outcome with resveratrol specifically.

The estrogenic concern is more relevant to women who use the LNG-IUD for heavy menstrual bleeding (HMB) management or endometrial protection during systemic estrogen therapy than to those using it purely for contraception.

How the levonorgestrel IUD works (and why local delivery changes everything)

The levonorgestrel IUD is approved by the FDA for contraception (Mirena up to 8 years, Kyleena up to 5 years) and, for the 52 mg device specifically, for management of heavy menstrual bleeding. The contraceptive mechanism is local: levonorgestrel thickens cervical mucus to block sperm, suppresses endometrial proliferation, and in some women suppresses ovulation intermittently.

Systemic exposure is genuinely low

Because the hormone is released at roughly 20 mcg per day initially, declining to about 10 mcg per day at 5 years, circulating progestin levels are a fraction of what you would encounter with oral contraceptives or hormonal patches. This is the core reason that drug interactions affecting hepatic CYP enzymes matter less with an IUD than with any oral hormonal method.

Endometrial effects and why estrogenic supplements deserve more scrutiny here

For women who rely on the LNG-IUD to manage HMB, the endometrium becoming thinner is the mechanism of benefit. ACOG Practice Bulletin 128 supports LNG-IUDs as a first-line option for HMB. Introducing a supplement with even weak estrogenic properties could theoretically blunt endometrial thinning, allowing heavier periods to return. The effect of resveratrol on LNG-IUD-mediated endometrial suppression has not been studied, so this remains speculative rather than confirmed.

What the evidence actually shows (and where it runs out)

No published clinical trial has directly assessed resveratrol co-administration in women using a levonorgestrel IUD. The available evidence falls into three categories, each with important limits.

In vitro and animal pharmacology

Lab studies confirm that resveratrol inhibits CYP3A4, inhibits aromatase at high concentrations, and activates estrogen receptors at low concentrations. A 2002 study in Cancer Research found that resveratrol acted as an agonist at ERalpha and ERbeta at concentrations below 10 micromolar, shifting to a partial antagonist role at higher concentrations. These are in vitro concentrations that do not map cleanly to human plasma levels from oral supplementation, where peak concentrations after a 250 mg dose are typically below 2 micromolar.

Human pharmacokinetic data

A 2010 crossover study in healthy adults found that resveratrol 1,000 mg inhibited CYP3A4 activity by approximately 34 percent as measured by midazolam clearance. That degree of inhibition would be relevant for an oral pill user. For an IUD user with plasma levonorgestrel at 150 to 200 pg/mL, a 34 percent rise would bring levels to roughly 200 to 270 pg/mL, which is still far below therapeutic thresholds for any known toxicity and well within normal device-to-device variation.

Clinical outcome data in women

No study has tracked bleeding patterns, endometrial thickness, or contraceptive failure in LNG-IUD users taking resveratrol. The Natural Medicines database rates the evidence for this specific combination as insufficient to grade. The honest position is that we are extrapolating from pharmacological principles, not direct trial data. Women have been consistently under-represented in supplement-drug interaction research, and this gap is real.

Life-stage considerations: how your hormonal context changes the picture

Reproductive years (ages 18 to 40): using Mirena or Kyleena for contraception

If you are premenopausal and using an LNG-IUD primarily for contraception, the resveratrol interaction risk is low. Contraceptive failure risk from resveratrol is theoretical and unsupported by clinical evidence. Many women in this group take resveratrol for skin, athletic recovery, or general antioxidant purposes. Standard supplement doses (250 mg to 500 mg per day) carry no documented contraceptive risk with an IUD.

Monitor your bleeding pattern. If you add resveratrol and notice heavier periods or spotting returning after a period of amenorrhea, that is worth mentioning to your clinician, even though causation is unproven.

Perimenopause (ages 40 to 55): the most common context for this combination

This is where the question gets more clinically layered. Many perimenopausal women use the 52 mg LNG-IUD for two reasons simultaneously: to manage erratic, heavy periods driven by anovulatory cycles, and, when combined with systemic estrogen therapy, for endometrial protection under the Menopause Society (NAMS) guidance. Resveratrol is aggressively marketed to perimenopausal women for vasomotor symptoms, cardiovascular protection, and "estrogen-like" support.

In this group, resveratrol's weak estrogenic activity and aromatase-modulating properties deserve more attention. A 2014 randomized trial in postmenopausal women (the RESHAW study, n=80) found that 75 mg of trans-resveratrol twice daily over 14 weeks improved vasomotor symptoms and verbal memory compared with placebo. The trial did not assess endometrial thickness. If you are perimenopausal, using the LNG-IUD for endometrial protection during systemic hormone therapy, and adding resveratrol, your prescribing clinician should know about the supplement so they can monitor endometrial response.

Postmenopause: LNG-IUD for endometrial protection during HRT

The 52 mg LNG-IUD is used off-label as the progestogen component of menopausal hormone therapy in many countries, though in the United States the FDA-approved options for endometrial protection are oral or transdermal progestins. Postmenopausal women interested in resveratrol for cardiovascular or bone benefits should discuss both interventions with their provider as a package, not separately.

Pregnancy, lactation, and contraception: required safety information

Levonorgestrel IUDs and pregnancy: The LNG-IUD is contraindicated in confirmed or suspected pregnancy. If pregnancy occurs with an IUD in place, there is an increased risk of ectopic pregnancy and serious infection. The device should be removed if pregnancy is confirmed and removal is possible. Levonorgestrel itself is a Pregnancy Category X agent in the context of established pregnancy with an IUD in place. Fertility typically returns rapidly after IUD removal.

Resveratrol in pregnancy: Resveratrol should not be taken during pregnancy. Animal studies have found dose-dependent adverse fetal effects. A 2016 review in Reproductive Toxicology found that resveratrol at high doses disrupted placental development in rodent models. Human data are absent. No safe dose in pregnancy has been established. If you are planning to conceive and want to continue resveratrol, discuss stopping it at least one month before attempting conception.

Resveratrol in lactation: Transfer of resveratrol into breast milk is not well characterized. No human lactation pharmacokinetic studies are available. Given the unknown risk and the presence of alternative options for maternal health support, resveratrol is generally not recommended during breastfeeding. The LactMed database does not currently list resveratrol with established safety data for nursing women.

Contraception note: The LNG-IUD is itself a highly effective contraceptive method (<1% annual failure rate for Mirena). No additional contraceptive precaution is needed specifically because of resveratrol co-use, given the absence of a confirmed pharmacokinetic interaction at typical supplement doses.

Who this combination is likely fine for, and who should talk to their clinician first

Not every woman using an LNG-IUD faces the same risk profile with resveratrol. Here is a practical stratification.

Likely low concern

• You use Mirena or Kyleena solely for contraception, are premenopausal, and have a stable bleeding pattern.
• You are taking a standard supplement dose of 250 mg to 500 mg per day.
• You have no history of estrogen-sensitive conditions.
• Your periods stopped or became very light after IUD insertion and have remained that way.

Worth a conversation with your clinician

• You use the LNG-IUD primarily to manage HMB and your periods have returned or become heavier since adding resveratrol.
• You are perimenopausal and using the LNG-IUD alongside systemic estrogen therapy, meaning the IUD is your sole source of endometrial protection.
• You take resveratrol at doses above 1,000 mg per day.
• You have a personal or family history of estrogen-receptor-positive breast cancer and are using resveratrol with the idea that it is a "safe" estrogen alternative.
• You are planning pregnancy soon.

What to do if you are already taking both

First, there is no emergency. The absence of a confirmed dangerous interaction means you do not need to stop either intervention abruptly. Take these practical steps.

Track your bleeding. Use a period-tracking app or a simple calendar to log any changes in flow, spotting, or cycle length in the 4 to 8 weeks after starting resveratrol. This gives your clinician objective data.

Tell your provider at your next visit. Bring the supplement bottle or note the brand, dose, and formulation (regular resveratrol versus trans-resveratrol). Some formulations include piperine (black pepper extract), which is a stronger CYP3A4 inhibitor and adds a layer of complexity that your prescriber should know about. A 2012 study found that piperine inhibited CYP3A4 activity more potently than resveratrol alone in human liver microsomes.

If your provider needs a starting reference, the Natural Medicines database and the NIH Office of Dietary Supplements are acceptable clinical references for supplement-drug interaction screening, even though neither has a specific entry for this exact combination.

Resveratrol, PCOS, endometriosis, and other conditions that often co-exist with IUD use

Many women who ask this question also live with conditions for which resveratrol has been studied separately.

PCOS: A 2018 randomized controlled trial in Fertility and Sterility (n=34) found that resveratrol 1,500 mg per day over 3 months reduced total testosterone and DHEAS in women with PCOS compared with placebo. Women with PCOS sometimes use the LNG-IUD for menstrual regulation or endometrial protection alongside androgen-lowering strategies. This trial suggests a potentially beneficial hormonal effect of resveratrol in PCOS, though the study was small and short-term.

Endometriosis: Resveratrol has anti-proliferative effects on endometrial stromal cells in vitro. A 2012 Brazilian RCT published in the Journal of the Medical Association of Thailand found that resveratrol 30 mg per day reduced pelvic pain scores in women with endometriosis over 6 months. The LNG-IUD is also used off-label for endometriosis-related pain. No trial has combined both interventions, but the pharmacological rationale for adjunctive use is not unreasonable. Talk to your gynecologist before combining treatments for endometriosis.

Female pattern hair loss and hormonal acne: Women with androgen-excess patterns sometimes use LNG-IUDs despite their androgenic progestin profile, or choose Kyleena (lower systemic exposure) to minimize androgen-related side effects. Resveratrol has some androgen-modulating properties in vitro. No clinical data guide this specific combination.

Dosing and formulation details that matter

Not all resveratrol supplements are the same. Most commercial supplements contain trans-resveratrol, the biologically active form. Bioavailability is low: oral bioavailability of free resveratrol is less than 1 percent in some studies due to rapid first-pass sulfation and glucuronidation. Formulations with liposomal delivery, micronization, or piperine are designed to overcome this.

The CYP3A4 inhibition seen in the Chow et al. 2010 crossover study used a dose of 1,000 mg. At 250 mg or 500 mg, the inhibitory effect on CYP3A4 is likely proportionally smaller, though the dose-response relationship for CYP inhibition in vivo has not been fully characterized for resveratrol.

If you choose to take resveratrol with an LNG-IUD, standard-dose trans-resveratrol (250 to 500 mg per day) without piperine represents the lowest-interaction-risk formulation available, based on current pharmacological principles.